Filing Flows › Stoke Therapeutics (STOK) › Q1 2026
Stoke Therapeutics (STOK) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Stoke Therapeutics (STOK) reported revenue of $6.2M for the first quarter 2026 (Q1 2026), -96% from a year earlier and +344% from the quarter before. Operating margin was -857.6%, net loss $50.0M (802.7% of revenue).
Stoke Therapeutics, Q1 2026: revenue $6.2M (-96% year over year), operating margin -857.6%, net loss $50.0M, operating cash flow −$60.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.2M | +344% | -96% |
| Operating profit | −$53.4M | — | -148% |
| Net earnings | −$50.0M | — | -144% |
| Operating cash flow | −$60.6M | — | -146% |
What changed
Revenue was $6.2M in Q1 2026, down 96% year over year and up 344% from the previous quarter.
Operating costs exceeded revenue by $53.4M, an operating margin of -857.6%. Total costs grew 26% against a revenue fall of 96%. The fastest-growing cost line was SG&A (+36%). The quarter ended with a net loss of $50.0M, narrower than the previous quarter's $57.9M loss.
Operating cash flow was −$60.6M. Non-cash charges added back $439K of depreciation and $8.8M of share-based compensation. Working capital and other items used $19.8M. Capital expenditures of $353K exceeded it, leaving free cash flow of −$60.9M.
Questions
What was Stoke Therapeutics' revenue in the first quarter 2026?
Stoke Therapeutics (STOK) reported revenue of $6.2M for the first quarter 2026 (Q1 2026), -96% from a year earlier and +344% from the quarter before.
Was Stoke Therapeutics profitable in the first quarter 2026?
Operating loss was $53.4M (-857.6% of revenue) and net loss $50.0M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.